|
|
|
« BACK
NEWS & PRESS RELEASE ARCHIVES
Monday, October 24, 2005 :: European Institute of Oncology Receives CT Laser Breast Imaging System Wednesday, October 19, 2005 :: IMAGING DIAGNOSTIC SYSTEMS TO PARTICIPATE IN VENEZUELAN CONGRESS Wednesday, October 12, 2005 :: REPORTS STRONG FIRST QUARTER REVENUE Monday, August 22, 2005 :: IDSI EXPANDS INTO SOUTH KOREA Tuesday, July 5, 2005 :: CT LASER MAMMOGRAPHY STUDY FEATURED IN PROMINENT PEER-REVIEWED JOURNAL
FORT LAUDERDALE, Fla., Oct. 24--Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) announced today that a CT Laser Mammography (CTLM®) system will be installed at the prestigious European Institute of Oncology (EIO) in Milan, Italy. Studies will be performed under the auspices of Professor Umberto Veronesi, Scientific Director.
Professor Veronesi is the Chairman of the Institute's Scientific Committee, a group that suggests new areas of research for the Institute and monitors the research that is underway. Veronesi is also a member of the Institute's Research Committee, which decides the Institute's research strategy and approves research plans.
"We are extremely pleased that Professor Veronesi and his team will be using CTLM. His group has led many important studies; it is fitting that our revolutionary technology to improve the accuracy of breast cancer detection techniques and to improve case management move forward under their capable direction. We especially thank our local distributor for making this arrangement possible," stated Tim Hansen, Chief Executive Officer, Imaging Diagnostic Systems, Inc. "This marks our fourth sale in Italy and our sixth installation in the country -- a tremendous start for our clinical and commercialization efforts."
Dr. Enrico Cassano, Director of Breast Imaging at the Institute, said, "We are pleased to have this opportunity to work with the CTLM laser breast scanner. It has been used in research and in a clinical capacity at other international sites; now, we will add our expertise to that of the facilities working with this emergent modality. We are confident that our results will confirm the capabilities of CTLM."
The European Institute of Oncology is a comprehensive cancer center, providing diagnostic services and treatment while conducting research and participating in clinical trials. It is one of 30 institutes in Italy declared a Research Institute of Public Interest by the Italian government, a designation which reflects the strong national and international significance of the institutes to which the title is bestowed.
The sale, arranged through an IDSI distributor, was recognized in the fiscal quarter ending September 30, 2005.
The CTLM® system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
IMAGING DIAGNOSTIC SYSTEMS TO PARTICIPATE IN VENEZUELAN CONGRESS
Lectures Introduce CT Laser Mammography to the Region
Fort Lauderdale, Florida, October 19, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that Jose Cisneros, M.D., Ph.D., IDSI Associate Director of Clinical Research, will present two lectures at the Tenth Venezuelan Congress of Radiology and Diagnostic Imaging.
As part of a symposium on women’s health, Dr. Cisneros will discuss the scientific and clinical fundamentals of the CTLM system as well as the role of angiogenesis in the early detection of cancer.
The lectures will introduce the concept of CT Laser Mammography to the region through IDSI’s market development initiative in South America. CTLM was launched in Latin and South America with an installation in Argentina and two lectures at the Argentinean Congress of Radiology and Diagnostic Imaging. Based on the scientific and commercial interest generated, IDSI will continue to form partnerships, gain sites, and contribute to congresses and symposia in South America.
“The opportunities that we have had in South America have enabled us to introduce the CTLM system to two separate regions, reaching many influential medical centers and prominent physicians. We are very pleased with the exposure we have gained and look forward to the success of the development initiative,” stated Deborah O’Brien, IDSI Senior Vice President.
The Venezuelan Congress is an annual radiology meeting that attracts physicians from Colombia, Venezuela, the Caribbean, and Central America. This year’s meeting is a joint event with the Radiological Society of Panama.
The CTLMâ system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
IMAGING DIAGNOSTIC SYSTEMS REPORTS STRONG FIRST QUARTER REVENUE
Record Five CTLM® Systems Sold
Fort Lauderdale, Florida, October 12, 2005—Imaging Diagnostic Systems, Inc., (OTCBB: IMDS) reported today that a record five CT Laser Mammography (CTLM®) systems were sold in the quarter ending September 30, 2005.
In the quarter ending September 30, 2005, IDSI is expected to report net sales of $671,750, up from the $374,952 reported for the entire previous fiscal year ending June 30, 2005.
“Our first fiscal quarter was a clear endorsement of the effectiveness of our global commercialization program and growing market acceptance of laser breast scanning. Four of the five sales had been announced via press releases; details of the fifth will soon be released. We are gaining traction in several key geographic areas as our distributors and clinical partner sites gain experience with this new technology. It is an exciting time,” stated Tim Hansen, IDSI Chief Executive Officer.
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
IDSI EXPANDS INTO SOUTH KOREA
New Distributor Plans to Install CT Laser Mammography System
Fort Lauderdale, Florida, August 22, 2005—Imaging Diagnostic Systems, Inc., (OTCBB: IMDS) announced today the appointment of LeoMedics Co., Ltd. as the exclusive distributor of CT Laser Mammography (CTLM®) in South Korea. LeoMedics intends to install a CTLM system before the end of the year to promote the new technology in the region.
“We are very pleased to announce LeoMedics as our distributor. LeoMedics has a history of excellent customer service and a broad medical product line. LeoMedics is a distributor for Philips Medical Systems, International Technidyne Corp., Rigel Medical, Ltd., MIPM GmbH, and Elltec Co., Ltd. Their business model supports the expansion of their medical product line into breast imaging via our revolutionary technology,” said Mr. Janusz Ostrowski, IDSI Vice President of International Sales. “We expect them to establish a CTLM clinical site very soon.”
South Korea is a prosperous country with a well-established health care system and distinguished research institutions. With a population approaching 50 million, South Korea faces the challenges of screening for and diagnosing breast cancer. Breast cancer is one of the most prevalent types of cancer for women in South Korea, with the number of deaths from the disease increasing annually.
“After researching the CTLM market potential and visiting the IDSI factory, we were very happy to sign an exclusive distribution contract. Korea has 970 hospitals and thousands of medical clinics. Mammography systems account for 7% of the general imaging market, almost $10 million USD. LeoMedics turnover grew 84% in 2004; we are expecting more than 20% growth this year. The CTLM should help us grow rapidly because it is the first of its kind, a diagnostic device that utilizes laser technology in Diagnostic Imaging. We are very excited to be the company that will introduce this innovative technology to South Korea,” Mr. Hi-Je Yun, LeoMedics Director of Marketing, stated.
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
CT LASER MAMMOGRAPHY STUDY FEATURED IN PROMINENT PEER-REVIEWED JOURNAL
Study Demonstrates Malignant Lesions Visualized By CTLMâ
Fort Lauderdale, Florida, July 5, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that a study demonstrating the potential of CTLM to characterize benign and malignant tumors was featured in the June issue of Investigative Radiology.
The study, conducted by the Department of Radiology and the Department of Gynecology and Obstetrics at the Medical University of Vienna, Austria, analyzed 105 breast lesions discovered in 100 women through x-ray mammography. Lesions were investigated through CTLM images and additional mammograms. In the evaluation of each lesion, CTLM images and mammograms were interpreted without the information provided by the other modality. Histologic analysis was used to verify the results.
A significant correlation was observed between absorption of laser light as seen on CTLM scans and the presence of malignant breast tumors. Absorption was seen more often in more aggressive cancers, which seem to develop more new blood vessels than less aggressive cancers. Researchers were also able to gain information about the shape and appearance of both benign and malignant tumors through the images obtained from CTLM scans.
“We observed that CTLM was able to visualize the majority of malignant lesions in our study. Thus, we believe that optical mammography is a promising technology which warrants further investigation,” stated Dr. Daniel Flöry of the Department of Radiology.
Investigative Radiology features studies conducted and evaluated by researchers throughout the world. The journal covers a range of radiological topics from diagnostic imaging and the use of radioactive isotopes to modalities such as computed tomography, positron emission tomography, magnetic resonance imaging, and ultrasound.
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
